Compounds and methods for diagnosis and treatment of viral infections
AssigneeNavidea Biopharmaceuticals, Inc.
InventorsFrederick O. Cope, David A. Ralph
Life of this patent
Estimating the term…
Abstract
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for diagnosing and/or treating flaviviridae-family viruses including Zika virus, dengue virus, and yellow fever.
Claims12
A method of treating a disease comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
- wherein each X is independently H, L1-A, or L2-R;
- each L1 and L2 are independently linkers;
- each A independently comprises a therapeutic agent or a detection label or H;
- each R independently comprises a CD206 targeting moiety or H;
- and n is an integer greater than zero;
- and wherein at least one R is a CD206 targeting moiety and at least one A is a chemotherapeutic agent wherein the disease is selected from Zika Virus, Yellow Fever, and Dengue Fever.
A method of targeting zika virus by targeting macrophages comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
- wherein each X is independently H, L1-A, or L2-R;
- each L1 and L2 are independently linkers;
- each A independently comprises a therapeutic agent or a detection label or H;
- each R independently comprises a CD206 targeting moiety or H;
- and n is an integer greater than zero;
- and wherein at least one R is a CD206 targeting moiety and at least one A is a chemotherapeutic agent to treat the disease and decrease the amount of disease causing virus.
A method of treating a disease caused by infection by a flaviviridae family virus comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
- wherein each X is independently H, L1-A, or L2-R;
- each L1 and L2 are independently linkers;
- each A independently comprises a therapeutic agent or a detection label or H;
- each R independently comprises a CD206 targeting moiety or H;
- and n is an integer greater than zero;
- and wherein at least one R is a CD206 targeting moiety and at least one A is doxorubicin or dexamethasone.
Dependencies are inferred from the claim text.